值得关注的是，在近视低龄化趋势显著的当下，高度近视若不及时干预可能引发视网膜脱离等严重眼部 疾病。目前，SVS镜因安全廉价被广泛使用，而OK镜和DS镜作为新型手段逐渐受到关注。 研究团队表示，本研究也存在局限性，未来还需进一步研究不同品牌镜片的差异，为个性化矫正方案提 供更精准的依据。 中证报中证网讯(王珞)近日，辽宁何氏医学院余斯乐副教授团队联合沈阳何氏眼科（301103）医院临床 研究部专家秦光浩团队等，共同合作在眼科国际期刊《BMJ OPEN OPHTHALMOLOGY》上发表研究 论文，评估并比较我国近视儿童及青少年佩戴角膜塑形镜(OK镜)、离焦眼镜(DS镜)和单光眼镜(SVS镜) 的视力相关生活质量以及临床疗效，为近视光学干预的临床选择提供了重要参考。 近年来，何氏眼科积极响应"光明工程"国家倡议，联合辽宁何氏医学院和何氏眼产业集团，依托辽宁省 青少年近视防控基地和沈阳市数字化青少年近视防控重点实验室，借助大数据、人工智能、基因等新技 术，构建"365近视防控体系"。该体系以"精准"为首要原则，根据基因检测和视力检查数据定制个性化 方案，弥补传统模式不足；涵盖近视发展全周期，包含预防、预警、控制和干 ...

Core Viewpoint - The research published in the international ophthalmology journal "BMJ OPEN OPHTHALMOLOGY" evaluates and compares the vision-related quality of life and clinical efficacy of different optical interventions for myopic children and adolescents in China, providing important references for clinical choices in myopia optical intervention [1] Group 1: Industry Context - The prevalence of myopia among children and adolescents in China is increasing, characterized by younger onset and more severe cases, which has raised significant social concerns [1] - The company actively responds to the national initiative "Light Project" by collaborating with various institutions to address myopia prevention and control [1] Group 2: Technological Integration - The establishment of the "365 Myopia Prevention and Control System" incorporates new technologies such as big data, artificial intelligence, and genetics to create personalized intervention plans based on genetic testing and vision examination data [1] - The system covers the entire myopia development cycle, including prevention, early warning, control, and intervention, providing continuous management services [1]

Group 1: Mergers and Acquisitions Strategy - The company adheres to a cautious and prudent investment principle when selecting merger targets, focusing on strategic alignment, compliance, value assessment, and acquisition methods [2][3][7] - The company aims to acquire medical targets in the ophthalmology consumer healthcare sector and upstream/downstream industry chain extensions [7][8] Group 2: Research and Development Investments - In 2024, the company increased R&D investments significantly, focusing on AI-assisted diagnosis and new intelligent devices, which are expected to enhance diagnostic efficiency and service capabilities [4][8][17] - The company achieved a post-operative satisfaction rate of over 98% through advanced equipment and innovative surgical techniques [3][4] Group 3: Financial Performance - The company reported a net profit of -27.4 million yuan in 2024, with a net profit margin of -3.22%, attributed to intensified industry competition and changes in medical insurance payment methods [8][9] - In Q1 2025, the company achieved a net profit of 32.5 million yuan, with a net profit margin of 11.16%, indicating a recovery compared to the previous year [8] Group 4: Internet Healthcare Development - The company's online healthcare platform has over 900,000 users and 120 online doctors, providing a range of services including consultations and health management [6][8] Group 5: Market Competition and Product Development - The company focuses on differentiated technology and customized products, such as the "Zhaoxing lens" and the "365 Myopia Prevention System," to strengthen its market position in vision care [9][10] - The company is actively monitoring advancements in gene therapy and AI-assisted surgical planning to maintain its competitive edge [8][9] Group 6: Social Responsibility and ESG Initiatives - The company has trained over 50,000 grassroots doctors and healthcare managers, contributing to public health and eye care accessibility [23][24] - The company integrates ESG principles into its operations, focusing on sustainable development and community health initiatives [25][26]